Timothy Eugene Sullivan Sells 10,287 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 10,287 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $223,947.99. Following the completion of the transaction, the chief financial officer owned 93,901 shares of the company’s stock, valued at approximately $2,044,224.77. This represents a 9.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Tuesday, January 20th, Timothy Eugene Sullivan sold 2,892 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $19.79, for a total value of $57,232.68.
• On Tuesday, January 13th, Timothy Eugene Sullivan sold 3,856 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $22.19, for a total transaction of $85,564.64.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $21.76 on Friday. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The company’s fifty day simple moving average is $23.02 and its 200 day simple moving average is $23.56. Apellis Pharmaceuticals, Inc. has a 1-year low of $16.10 and a 1-year high of $30.91. The company has a market cap of $2.75 billion, a price-to-earnings ratio of 70.18 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Thursday, October 30th. The company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. The company had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The company’s quarterly revenue was up 133.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.46) EPS. On average, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Key Headlines Impacting Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Bank of America upgraded Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Wednesday. Citigroup reduced their price objective on shares of Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 31st. William Blair reiterated an “outperform” rating on shares of Apellis Pharmaceuticals in a report on Monday, December 15th. Wall Street Zen upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, HC Wainwright reduced their target price on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. Twelve analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $33.53.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently modified their holdings of APLS. PNC Financial Services Group Inc. increased its position in Apellis Pharmaceuticals by 0.8% during the second quarter. PNC Financial Services Group Inc. now owns 58,856 shares of the company’s stock worth $1,019,000 after acquiring an additional 465 shares during the period. Wedmont Private Capital grew its position in shares of Apellis Pharmaceuticals by 4.1% during the 4th quarter. Wedmont Private Capital now owns 11,883 shares of the company’s stock worth $315,000 after purchasing an additional 468 shares in the last quarter. Amalgamated Bank increased its holdings in shares of Apellis Pharmaceuticals by 6.9% during the third quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock worth $196,000 after purchasing an additional 563 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Apellis Pharmaceuticals by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock valued at $84,000 after buying an additional 655 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after buying an additional 855 shares during the period. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.